Dr. Zhi Li 李智
Chief Physician
Department of General Surgery, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and surgical treatment of common gastrointestinal tumors, with a focus on laparoscopic and minimally invasive techniques.
Dr. Li holds an MD and serves as Deputy Director of General Surgery and Director of the Henan Gastrointestinal Tumor Minimally Invasive Diagnosis and Treatment Center. Graduating from Henan Medical University in 1994, Dr. Li has worked at Henan Cancer Hospital since then and was a visiting scholar in Germany in 2010. Research focuses on surgical and laparoscopic treatment of gastrointestinal tumors.
Professional roles
- Member, Young and Middle-Aged Surgeons Committee, Surgical Oncology Branch, Chinese Medical Doctor Association
- Member, Tumor Minimally Invasive Therapy Professional Committee, China Anti-Cancer Association
- Vice Chair, Tumor Minimally Invasive Therapy Professional Committee, Henan Anti-Cancer Association
- Member, Oncology Professional Committee, Henan Branch, Chinese Medical Association
Name order: in Chinese the family name comes first (Li Zhi). Papers usually list the name as Zhi Li or Li Z.
Selected publications
39 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biochim Biophys Acta Mol Basis Dis, 2027 (senior author): MX1 promotes gastric cancer cell migration via inhibiting ANXA2 ubiquitination and degradation. PubMed 42641668
- Eur J Pharmacol, 2026 (senior author): The matrikine proline-glycine-proline links neutrophilic inflammation and tissue remodeling in colorectal cancer. PubMed 42933763
- Oncol Rep, 2026 (senior author): E3 ubiquitin ligase RNF40: Structure, function and its context‑dependent roles in tumorigenesis (Review). PubMed 42059264
- Front Oncol, 2026 (senior author): The vesicle transport gene SEC23A is a novel prognostic indicator and therapeutic target in gastric cancer. PubMed 42052483
- Oncol Rep, 2026 (senior author): Alternative splicing in cancer drug resistance: Mechanisms and therapeutic prospects (Review). PubMed 41347834
- Surgery, 2026 (senior author): Neutrophil-to-lymphocyte ratio as an early predictor of anastomotic leakage after rectal cancer surgery. PubMed 41151491
- Genomics, 2025 (senior author): Identifying and characterizing a novel APC promoter 1B deletion in a Chinese family with familial adenomatous polyposis. PubMed 41038404
- J Gastrointest Oncol, 2023 (senior author): Development and validation of a nomogram to predict pathological complete response in patients with locally advanced gastric adenocarcinoma treated with neoadjuvant chemotherapy in combination with PD-1 antibodies. PubMed 38196541
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion